Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions

Abstract

The effect of the treatment with glucagon-like peptide (GLP)-1 receptor agonists on gastric emptying in patients with diabetes with and without gastroparesis is analysed. Patients with type 2 diabetes mellitus subjected to GLP-1 receptor agonist therapy with exenatide were examined before and shortly after initiation of treatment. Gastric half-emptying time was determined by ¹³C-octanoic breath test; routine laboratory parameter as well as active GLP-1, ghrelin, leptin, insulin, proinsulin and C-peptide levels were determined in fasting state as well as postprandial secretion within 1 h after a standardised meal. Thirty patients’ data sets were available for evaluation, of those 20 patients had no gastroparesis and 10 patients showed pathological results following the breath test. Gastric half-emptying time was prolonged in nearly all patients who presented without gastroparesis at initiation of treatment with GLP-1 receptor agonists, only 2 patients with pre-existing mild gastroparesis had worsening of gastric emptying. No effect was detected on leptin and ghrelin levels. Postprandial GLP-1 concentrations measured as AUC after meal decreased significantly. Fasting insulin and C-peptide levels increased significantly without effect on postprandial levels. Proinsulin levels – fasting as well as AUC – decreased non-significantly. Patients reported comparable perception of therapeutic effects. Treatment with GLP-1 receptor agonists may be applied in patients with pre-existing gastroparesis; no effect in terms of worsening of symptoms compared to those without gastroparesis was detected. Patients reported outcome was independent from underlying gastroparesis. Negative effects on gastric emptying were only detected in patients without or with mild gastroparesis.

Key words

diabetic gastroparesis - incretin therapy - breath test - gastric half-emptying time

^* Equal authorship: Christelle Beti and Bernd Stratmann.

• References

• 1 Hellstrom PM. GLP-1: Broadening the incretin concept to involve gut motility. Regul Pept 2009; 156: 9-12
• 2 Horowitz M, O’Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: Clinical significance and treatment. Diabet Med 2002; 19: 177-194
• 3 Parkman HP, Camilleri M, Farrugia G, McCallum RW, Bharucha AE, Mayer EA, Tack JF, Spiller R, Horowitz M, Vinik AI, Galligan JJ, Pasricha PJ, Kuo B, Szarka LA, Marciani L, Jones K, Parrish CR, Sandroni P, Abell T, Ordog T, Hasler W, Koch KL, Sanders K, Norton NJ, Hamilton F. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroent Motil 2010; 22: 113-133
• 4 Fraser R, Horowitz M, Maddox A, Dent J. Dual effects of cisapride on gastric emptying and antropyloroduodenal motility. Am J Physiol 1993; 264: G195-G201
• 5 Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Digest Dis Sci 1998; 43: 2398-2404
• 6 Kashyap P, Farrugia G. Diabetic gastroparesis: What we have learned and had to unlearn in the past 5 years. Gut 2010; 59: 1716-1726
• 7 Kempler P, Varadi A, Szalay F, Kadar E, Regos E, Veszter B. Gastrointestinal aspects of autonomic neuropathy. Falk Symp 1989; 50: 602-606
• 8 Undeland KA, Hausken T, Svebak S, Aanderud S, Berstad A. Wide gastric antrum and low vagal tone in patients with diabetes mellitus type I compared to patients with functional dyspepsia and healthy individuals. Digest Dis Sci 1996; 41: 9-16
• 9 Harberson J, Thomas RM, Harbison SP, Parkman HP. Gastric neuromuscular pathology in gastroparesis: analysis of full-thickness antral biopsies. Dig Dis Sci 2010; 55: 359-370
• 10 Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol 2011; 9: 5-12
• 11 Shah V, Lyford G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology 2004; 126: 903-913
• 12 Lin Z, Forster J, Sarosiek I, McCallum RW. Treatment of diabetic gastroparesis by high-frequency gastric electrical stimulation. Diabetes Care 2004; 27: 1071-1076
• 13 Beckers EJ, Jeukendrup AE, Brouns F, Wagenmakers AJ, Saris WH. Gastric emptying of carbohydrate–medium chain triglyceride suspensions at rest. Int J Sports Med 1992; 13: 581-584
• 14 Nilsson PH. Diabetic gastroparesis: A review. J Diabetes Complicat 1996; 10: 113-122
• 15 Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G. Measurement of gastric emptying rate of solids by means of a carbonlabeled octanoic acid breath test. Gastroenterology 1993; 104: 1640-1647
• 16 Bruno G, Lopetuso LR, Ianiro G, Laterza L, Gerardi V, Petito V, Poscia A, Gasbarrini A, Ojetti V, Scaldaferri F. 13C-octanoic acid breath test to study gastric emptying time. Eur Rev Med Pharmacol Sci 2013; 17 (Suppl. 02) 59-64
• 17 Pouwer F, Snoek FJ, van der Ploeg HM, Heine RJ, Brand AN. A comparison of the standard and the computerized versions of the well-being questionnaire (WBQ) and the diabetes treatment satisfaction questionnaire (DTSQ). Quality Life Res 1998; 7: 33-38
• 18 McHorney CA, Ware Jr. JE, Lu JF, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66
• 19 McHorney CA, Ware Jr. JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-263
• 20 Ware Jr. JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483
• 21 Kolotkin RL, Head S, Hamilton M, Tse CK. Assessing impact of weight on quality of life. Obes Res 1995; 3: 49-56
• 22 de Clercq N, Frissen MN, Groen AK, Nieuwdorp M. Gut Microbiota and the Gut-Brain Axis: New insights in the pathophysiology of metabolic syndrome. Psychosomat Med 2017; 79: 874-879